Elizabeth Homans - 13 Sep 2021 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Role
Chief Executive Officer, Director
Signature
/s/ Heather Turner, as Attorney-in-Fact
Issuer symbol
LYEL
Transactions as of
13 Sep 2021
Net transactions value
$0
Form type
4
Filing time
14 Sep 2021, 16:17:16 UTC
Previous filing
16 Jun 2021
Next filing
18 Mar 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Option (right to buy) Award $0 +1,370,469 $0.000000 1,370,469 13 Sep 2021 Common Stock 1,370,469 $16.05 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares vest in equal monthly installments over the forty-eight months following September 13, 2021.